Summary of Use during Lactation

No information is available on the clinical use of moxetumomab pasudotox during breastfeeding. Moxetumomab pasudotox is a recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential anti-cancer activity. Because moxetumomab is a large protein molecule with a molecular weight of about 63,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, moxetumomab pasudotox should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Moxetumomab Pasudotox

CAS Registry Number

1020748-57-5

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal

Antineoplastic Agents